Investors bought shares of Tesaro Inc. (NASDAQ:TSRO) on weakness during trading on Friday. $50.28 million flowed into the stock on the tick-up and $39.91 million flowed out of the stock on the tick-down, for a money net flow of $10.37 million into the stock. Of all stocks tracked, Tesaro had the 6th highest net in-flow for the day. Tesaro traded down ($3.26) for the day and closed at $88.70

A number of research analysts recently issued reports on TSRO shares. Mizuho reissued an “outperform” rating and set a $67.00 price target on shares of Tesaro in a research report on Thursday, June 30th. FBR & Co reaffirmed a “buy” rating on shares of Tesaro in a report on Thursday, June 30th. Wells Fargo & Co. reaffirmed an “outperform” rating on shares of Tesaro in a report on Thursday, June 30th. Wedbush reaffirmed an “outperform” rating and issued a $72.00 target price on shares of Tesaro in a report on Wednesday, April 6th. Finally, Zacks Investment Research raised shares of Tesaro from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Tesaro presently has a consensus rating of “Buy” and a consensus target price of $73.91.

The company’s market capitalization is $4.07 billion. The company has a 50 day moving average price of $52.01 and a 200 day moving average price of $44.49.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by $0.53. The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $2.48 million. During the same quarter in the prior year, the company earned ($1.30) earnings per share. Equities research analysts anticipate that Tesaro Inc. will post ($7.16) EPS for the current fiscal year.

In related news, VP Jeffrey H. Hanke sold 12,500 shares of Tesaro stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total value of $929,375.00. Following the sale, the vice president now owns 12,500 shares of the company’s stock, valued at approximately $929,375. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Edward C. English sold 7,000 shares of Tesaro stock in a transaction on Friday, June 10th. The shares were sold at an average price of $40.75, for a total transaction of $285,250.00. Following the completion of the sale, the vice president now directly owns 3,500 shares in the company, valued at approximately $142,625. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors raised its position in shares of Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock worth $1,394,000 after buying an additional 330 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Tesaro by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,152 shares of the biopharmaceutical company’s stock worth $2,258,000 after buying an additional 752 shares during the last quarter. American Century Companies Inc. raised its position in shares of Tesaro by 6.7% in the fourth quarter. American Century Companies Inc. now owns 40,052 shares of the biopharmaceutical company’s stock worth $2,096,000 after buying an additional 2,501 shares during the last quarter. Rhumbline Advisers raised its position in shares of Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 1,915 shares during the last quarter. Finally, TD Asset Management Inc. raised its position in shares of Tesaro by 4.5% in the fourth quarter. TD Asset Management Inc. now owns 91,006 shares of the biopharmaceutical company’s stock worth $4,761,000 after buying an additional 3,900 shares during the last quarter.

TESARO, Inc (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.